News

SpeeDx Receives CE-IVD Mark for ResistancePlus™ MG

SpeeDx Pty. Ltd. has received CE-IVD marking for its ResistancePlus™ MG assay that detects both the sexually transmitted disease (STD) Mycoplasma genitalium (often referred to as M. genitalium or MG) and mutations in the 23S rRNA gene of the bacteria that have been shown to confer resistance to azithromycin, a commonly prescribed macrolide-based antibiotic.

“We are excited to receive CE-IVD marking for this revolutionary new benchmark for M. genitalium and antibiotic resistance testing,” said Colin Denver, CEO for SpeeDx. “As with the better known STD gonorrhoea, M. genitalium has developed serious treatment challenges because of the recent rise of antibiotic resistance.”

Read the full press release here